Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Shares Outstanding (Diluted Average) (2021 - 2025)

Sunshine Biopharma (SBFM) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $2.7 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Shares Outstanding (Diluted Average) rose 321.53% year-over-year to $2.7 million, compared with a TTM value of $2.7 million through Mar 2025, up 321.53%, and an annual FY2024 reading of $701749.0, up 5371.73% over the prior year.
  • Shares Outstanding (Diluted Average) was $2.7 million for Q1 2025 at Sunshine Biopharma, up from $701749.0 in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $25.4 million in Q2 2023 and bottomed at $12825.0 in Q4 2023.
  • Average Shares Outstanding (Diluted Average) over 5 years is $8.8 million, with a median of $4.0 million recorded in 2022.
  • The sharpest move saw Shares Outstanding (Diluted Average) crashed 99.92% in 2023, then skyrocketed 5371.73% in 2024.
  • Year by year, Shares Outstanding (Diluted Average) stood at $2.6 million in 2021, then skyrocketed by 481.18% to $15.2 million in 2022, then plummeted by 99.92% to $12825.0 in 2023, then surged by 5371.73% to $701749.0 in 2024, then soared by 285.22% to $2.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for SBFM at $2.7 million in Q1 2025, $701749.0 in Q4 2024, and $641310.0 in Q1 2024.